Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C

Table 3 Factors contributing to sustained virological response

	Univariate analysis		Multivariable analysis
	OR	P value	OR (95%CI)	P value
Sex (male to female)	2.25	0.0153
Age (< 60 yr to ≥ 60 yr)	1.79	0.0822
IL28B SNPs (rs8099917) (TT to TG/GG)	5.19	< 0.0001	8.24 (2.81-26.8)	< 0.0001
Hemoglobin level (≥ 140 g/L to < 140 g/L)	2.13	0.0245
Platelet count (≥ 150 × 109/L to < 150 × 109/L)	3.21	0.0005
Serum albumin (> 35 g/L to ≤ 35 g/L)	2.51	0.0308
Aspartate aminotransferase (< 50 U/L to ≥ 50 U/L)	2.30	0.0123
LDL-cholesterol (≥ 95 mg/dL to < 95 mg/dL)	4.39	< 0.0001
Response to previous PegIFN-α/RBV therapy (naïve/relapse to non-response)	6.38	< 0.0001	3.29 (1.14-9.46)	0.0281
VR at week 6	31.1	< 0.0001	63.8 (10.8-563)	< 0.0001

P value draws a comparison between SVR and non-SVR patients. SVR: Sustained virological response; IL28B: Interleukin 28B; SNP: Single-nucleotide polymorphism; LDL: Low-density lipoprotein; PegIFN: Pegylated interferon; RBV: Ribavirin; VR: Virological response.